Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy.
Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy.
复制标题
肝纤维化：治疗靶点和药物治疗进展
DOI：
10.3389/fcell.2021.730176
复制
发表时间：
2021
影响因子：
5.5
通讯作者：
Ye T
中科院分区：
文献类型：
--
作者：
Tan Z;Sun H;Xue T;Gan C;Liu H;Xie Y;Yao Y;Ye T
肝纤维化是由多种慢性肝损伤引起的异常创伤修复反应，以弥漫性细胞外基质（extracellular matrix，ECM）过度沉积和结缔组织异常增生为特征，可进一步发展为肝硬化、肝功能衰竭或肝癌。目前，慢性肝病伴肝纤维化在世界范围内已造成严重的发病率和死亡率，并呈上升趋势。虽然早期肝纤维化已被报道是可逆的，但逆转肝纤维化的详细机制仍不清楚，并且缺乏有效的治疗肝纤维化的方法。因此，抗纤维化药物的研究和开发仍然是当务之急。近年来，抗炎保肝、抑制肝星状细胞（hepatic stellate cells，HSC）的活化和增殖、减少ECM的过度产生和加速ECM的降解等策略成为抑制肝纤维化发生发展的重要手段。此外，基因治疗已被证明是一种很有前途的抗纤维化方法。在这里，我们提供了相关目标和正在开发的药物的概述。本文就其在肝纤维化治疗中的作用进行分类和总结，并探讨抗肝纤维化药物面临的挑战和发展方向。
Liver fibrosis is an abnormal wound repair response caused by a variety of chronic liver injuries, which is characterized by over-deposition of diffuse extracellular matrix (ECM) and anomalous hyperplasia of connective tissue, and it may further develop into liver cirrhosis, liver failure or liver cancer. To date, chronic liver diseases accompanied with liver fibrosis have caused significant morbidity and mortality in the world with increasing tendency. Although early liver fibrosis has been reported to be reversible, the detailed mechanism of reversing liver fibrosis is still unclear and there is lack of an effective treatment for liver fibrosis. Thus, it is still a top priority for the research and development of anti-fibrosis drugs. In recent years, many strategies have emerged as crucial means to inhibit the occurrence and development of liver fibrosis including anti-inflammation and liver protection, inhibition of hepatic stellate cells (HSCs) activation and proliferation, reduction of ECM overproduction and acceleration of ECM degradation. Moreover, gene therapy has been proved to be a promising anti-fibrosis method. Here, we provide an overview of the relevant targets and drugs under development. We aim to classify and summarize their potential roles in treatment of liver fibrosis, and discuss the challenges and development of anti-fibrosis drugs.
登录
查看更多内容
DOI：
10.1152/ajpgi.00162.2009
发表时间：
2009-10-01
影响因子：
4.5
作者：
Colmenero, Jordi;Bataller, Ramon;Gines, Pere
通讯作者：
Gines, Pere
影响因子：
7.3
作者：
Chen, A.;Zheng, S.
通讯作者：
Zheng, S.
影响因子：
25.7
作者：
Asrani, Sumeet K.;Devarbhavi, Harshad;Kamath, Patrick S.
通讯作者：
Kamath, Patrick S.
双氢青蒿素通过调节 PI3K/Akt 通路诱导肝星状细胞凋亡预防胆管结扎大鼠肝纤维化
影响因子：
4.6
作者：
Chen, Qin;Chen, Lianyun;Zheng, Shizhong
通讯作者：
Zheng, Shizhong
DOI：
10.1002/hep.27936
发表时间：
2015-10
期刊：
Hepatology (Baltimore, Md.)
影响因子：
--
作者：
Jiménez Calvente C;Sehgal A;Popov Y;Kim YO;Zevallos V;Sahin U;Diken M;Schuppan D
通讯作者：
Schuppan D